bevacizumab + gefitinib + icotinib + pemetrexed

This is a four-drug combination regimen consisting of bevacizumab, gefitinib, icotinib, and pemetrexed. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. - **Gefitinib** and **icotinib** are small molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), commonly used in EGFR-mutated non-small cell lung cancer (NSCLC). Both drugs inhibit EGFR signaling pathways involved in tumor cell proliferation and survival. - **Pemetrexed** is an antifolate chemotherapy agent that disrupts folate-dependent metabolic processes essential for cell replication. This combination has been investigated as a first-line treatment for advanced non-squamous NSCLC with EGFR mutations. Early-phase clinical studies suggest it may be well-tolerated and effective, showing high response rates and prolonged progression-free survival in this patient population[1][8].